328 was an Interlukin 2 treatment trial for subjects with a CD4 count between 50 and 300. Those subjects who received Interlukin had a statistically higher increase in their absolute CD4 counts after 60 weeks of treatment when compared to the patients who took a triple combination of HIV medications without Interlukin 2. A second plenary sponsored by the HIV complications group discussed new trials under development. These trials include a peginterferon trial for patients co-infected with HIV and HCV, treatment trials for patients with lipodystrophy, and trials for patients with elevated lipids and triglycerides. At request of a CAB member Karen Waterman met with the UTMB chaplain group at one of their weekly meetings.
Visitors are welcome.